RT Journal Article
SR Electronic
T1 Cerebrovascular Reactivity Following Spinal Cord Injury
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.06.28.22276567
DO 10.1101/2022.06.28.22276567
A1 Alexander Mark Weber
A1 Tom E. Nightingale
A1 Michael Jarrett
A1 Amanda H. X. Lee
A1 Olivia Campbell
A1 Matthias Walter
A1 Samuel J.E. Lucas
A1 Aaron Phillips
A1 Alexander Rauscher
A1 Andrei Krassioukov
YR 2022
UL http://medrxiv.org/content/early/2022/06/29/2022.06.28.22276567.abstract
AB Cervical and upper-thoracic spinal cord injury (SCI) commonly results in autonomic cardiovascular impairments. These impairments can lead to alterations in blood flow, cerebral perfusion pressure and ultimately tissue perfusion, which can lead to an elevated risk of stroke and global cognitive deficits. The aim of this study was to assess cerebrovascular reactivity (CVR) in both the grey matter (GM) and brainstem using functional magnetic resonance imaging (fMRI) in participants with SCI compared to non-injured controls. CVR represents the capacity of brain parenchyma to change cerebral blood flow in response to a vasoactive stimulus (e.g. carbon dioxide, CO2) or altered metabolic demand [e.g. neurovascular coupling (NVC)]. Thirteen participants (7 chronic SCI (all male, median age of 42 years), 6 controls (all male, median age of 33 years) were studied cross-sectionally. CVR was measured by assessing the MRI-blood oxygen level–dependent signal with hypercapnic challenge (controlled CO2 inhalation). The CVR outcome measure was assessed in three ways. Initially, CVR was calculated as is standard, via the linear, least-squares fit across the whole gas challenge protocol (CVRwhole). In addition, CVR was further decomposed into its dynamic (tau) and static components (steady state CVR; ssCVR). A 24-hour ambulatory blood pressure monitor was worn to capture free-living blood pressure outcomes. Our results showed a longer tau in the GM of SCI participants compared to controls (median of the difference = 3.0 seconds; p<0.05). Time since injury (TSI) displayed negative correlations with ssCVR in the GM and brainstem of SCI participants: RS=-0.77, p=0.041 and RS=-0.76, p=0.049, respectively, where RS is the Spearman’s rank Correlation Coefficient. Neurological level of injury (NLI), modified into an ascending, continuous numeric variable, was positively correlated with GM CVRwhole (RS=0.85, p=0.016), GM ssCVR (RS=0.95, p=0.001) and brainstem ssCVR (RS=0.90, p=0.006). Lower CVRwhole and ssCVR in the SCI-cohort was significantly (P<0.05) correlated with lower daytime blood pressure (RS≥ 0.81) and a higher frequency of hypotensive episodes (RS≥ -0.83). Thus, living with a SCI for a longer period of time, having a higher NLI and lower blood pressure are linked with poorer CVR outcomes. Our preliminary findings reveal an important difference between the cohorts in the dynamic CVR component, tau. Collectively, these results may partially explain the increased cerebrovascular health burden in individuals with SCI.HighlightsCVR is the change in blood flow in response to a vasodilatory stimulus (e.g., hypercapnia).Impaired CVR is linked with increased stroke risk and cognitive deficits.We investigated the dynamic and steady-state components of CVR using fMRI in individuals with a SCI.The dynamic component was significantly different compared to non-injured controls.CVR is significantly correlated with time since injury, level of injury and ambulatory daytime blood pressure.Competing Interest StatementThe authors have declared no competing interest.Funding StatementAlexander Weber was a recipient of a Child & Family Research Institute M.I.N.D. Postdoctoral Fellowship from BC Children's Research Institute, Vancouver, BC. Tom Nightingale (grant number 17767) and Matthias Walter (grant number 17110) were recipients of Michael Smith Foundation for Health Research Trainee Awards in conjunction with the International Collaboration on Repair Discoveries and Rick Hansen Foundation, respectively. The Phillips Lab is supported by the Wings for Life Foundation (Project Grant), Compute Canada (Resources for Research Groups), Natural Sciences and Engineering Research Council (Canada; Discovery Grant), the Canadian Institutes of Health Research (Project Grant), Alberta Innovates Health Solutions, Campus Alberta Neuroscience, the Libin Cardiovascular Institute of Alberta, the Hotchkiss Brain Institute, and the Rick Hansen Institute. Dr. Rauscher is supported by Canada Research Chairs. Dr. Krassioukov's laboratory is supported by funds from the Canadian Institutes for Health Research, Heart and Stroke Foundation, Canadian Foundation for Innovation, BC Knowledge Development Fund, and Craig H. Neilsen Foundation. Dr. Krassioukov is supported by an Endowed Chair, Department of Medicine, University of British Columbia. The study was funded by a Heart & Stroke Canada Foundation grant (#G-16-00012571. PI: Dr. Krassioukov). Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All participants provided written informed consent prior to participation in the study, which was approved by the University of British Columbia Clinical Research Ethics Board (H16-01458).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors